Filing Details

Accession Number:
0001562180-18-003130
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-29 16:22:19
Reporting Period:
2018-06-27
Accepted Time:
2018-06-29 16:22:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1100412 Array Biopharma Inc ARRY Pharmaceutical Preparations (2834) 841460811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1590157 R Andrew Robbins C/O Array Biopharma Inc.
3200 Walnut St
Boulder CO 80301
Coo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-27 32,068 $0.00 191,535 No 4 M Direct
Common Stock Disposition 2018-06-27 14,104 $18.50 177,431 No 4 F Direct
Common Stock Disposition 2018-06-27 17,964 $17.74 159,467 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2018-06-27 32,068 $0.00 32,068 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-08-18 No 4 M Direct
Footnotes
  1. Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II.
  2. Represents shares withheld to satisfy tax withholding obligations of the reporting person.
  3. These trades were made pursuant to a Rule 10b5-1 trading plan.
  4. The price reported for these shares is the weighted average sale price of transactions made at prices from $17.60 to $17.84. Details of actual prices for shares sold are available from the Issuer upon request.
  5. RSUs representing 32,068 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date.